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Objective.T oi n v e s t i g a t et h ed i ﬀerential protein proﬁle of human lung squamous carcinoma (HLSC) and normal bronchial
epithelium (NBE) and provide preliminary results for further study to explore the carcinogenic mechanism of HLSC. Methods.
Laser capture microdissection (LCM) was used to purify the target cells from 10 pairs of HLSC tissues and their matched NHBE,
respectively. A stable-isotope labeled strategy using iTRAQ, followed by 2D-LC/Q-STAR mass spectrometry, was performed to
separate and identify the diﬀerential expression proteins. Results.At o t a lo f9 6d i ﬀerential expression proteins in the LCM-puriﬁed
HLSC and NBE were identiﬁed. Compared with NBE, 49 proteins were upregulated and 47 proteins were downregulated in HLSC.
Furthermore, the expression levels of the diﬀerential proteins including HSPB1, CKB, SCCA1, S100A8, as well as S100A9 were
conﬁrmed by western blot and tissue microarray and were consistent with the results of quantitative proteomics. Conclusion.T h e
diﬀerent expression proteins in HLSC will provide scientiﬁc foundation for further study to explore the carcinogenic mechanism
of HLSC.
1.Introduction
Lung cancer ranks the ﬁrst in the morbidity and mortality
of human malignancies and keeps the leading position of all
common malignant tumors worldwide. Histopathologically,
lung cancers are classiﬁed into small cell lung cancer and
nonsmall cell lung cancer. The latter is further classiﬁed into
squamous cell carcinoma, adenocarcinoma, and large cell
caicinoma, according to its morphologic patterns. Among
which, squamous cell carcinoma is the most common,
which accounts for 40%–70% [1]. Squamous cell carcinoma
originates from the bronchial epithelial cell. Currently, the
mechanism of the initiation, development, and dissemina-
tion of human lung squamous carcinomas (HLSCs) is still
unclear.
Proteomics provides a new opportunity to reveal the car-
cinogenicmechanismofHLSC.Thecomparativeproteomics
compares the tumor and its origin tissue may reﬂect the
carcinogenesis. However, the main obstacle for proteomics
analysis is the heterogeneity of the soft tumor tissues. In
order to improve the accuracy of the results, it is necessary to
purify the target cells from the heterogeneous tissues. Laser
capture microdissection (LCM) is one of the best technolo-
gies for cell puriﬁcation [2–6]. The quantitative proteomics
isoneoftheemergingﬁeldsfortumorproteomicsstudy;iso-
tope labeling relative and absolute quantiﬁcation (iTRAQ) is
a new technique in quantitative proteomics, which could be
used to identify and quantify the protein expression levels
and identify the small changes of protein expression in
diﬀerent tissues.2 Journal of Biomedicine and Biotechnology
Inthisstudy,LCMwasusedtopurifythetargetcellsfrom
HLSC tissues and matched NBE; iTRAQ followed by 2D-
LC/Q-STAR mass spectrometry was performed to separate
and identify the diﬀerential expression proteins in LCM-
p u r i ﬁ e dH L S Ct i s s u e sa n dm a t c h e dN H B E .
2.MaterialsandMethods
2.1. Sample Collection, Laser Capture Microdissection, and
Protein Extraction. Twenty pairs of HSCL tissues and
matchednormalbronchialepitheliumtissuesfromtheLSCC
patients undergoing curative surgery and receiving nei-
ther chemotherapy nor radiotherapy were obtained from
Department of Cardiothoracic Surgery, The Second Xiangya
Hospitals of Central South University, China. The patients
signed an informed consent form for the study which was
approved by the local ethical committee. Samples were
diagnosedbyhistopathology.10pairsofthetissueswereused
for iTRAQ, and the other 10 pairs of the tissues for Western
b l o t t i n g ,r e s p e c t i v e l y .T i s s u e sw e r ef r o z e ni n−70◦C.
LCM was performed with a Leica AS LMD system to
purify the interest cells from HSCL tissues and matched NBE
tissues as previously described by us. Breiﬂy, frozen sec-
tions (8mm) from each HLSC and NBE tissues were pre-
pared using a Leica CM 1900 cryostat (Leica) at −25◦C.
The sections were placed on a membrane-coated glass slides
(Leica), ﬁxed in 75% alcohol for 30s, and stained with 0.5%
violet-free methyl green (Sigma). The stained sections were
air-dried and then subjected to LCM.
The microdissected cells were dissolved in lysis buﬀer
(7M urea, 2M thiourea, 65mM DTT, 0.1mM PMSF) at
4◦C for 1h and then centrifuged at 12000rpm for 30min
at 4◦C. The supernatant was collected, and the protein
concentration was determined by 2D Quantiﬁcation kit
(Amersham Biosciences). To diminish the eﬀect of sample
biological variation on the results of a proteomics analysis,
equalamountsofproteinsfromthemicrodissectedcellsof10
diﬀerent individuals were pooled to generate one common
sample iTRAQ labeling.
2.2. Protein Digestion and Labeling with iTRAQ Reagents.
Trypsin digestion and iTRAQ labeling were performed ac-
cording to the manufacturer’s protocol (Applied Biosys-
tems). Brieﬂy, 100μg protein of each pooled sample was re-
ducedandalkylatedandthendigestedovernightat37◦Cwith
trypsin (mass spectrometry grade; Promega) and labeled
with iTRAQ reagents (Applied Biosystems) as follows: NBE,
iTRAQ reagent 113; and HLSC, iTRAQ reagent 115. The
labeled digests were then mixed and dried.
2.3. Oﬀ-Line 2D LC-MS/MS. The mixed peptides were frac-
tionated by strong cation exchange (SCX) chromatography
on a 20AD HPLC system (Shimadzu) using a polysulfoethyl
column (2.1 × 100mm, 5μm, 300 ˚ A; The Nest Group Inc.)
as previously described by us [7]. Brieﬂy, the mixed peptides
were desalted with Sep-Pak Cartridge (Waters), diluted with
the loading buﬀer (10mM KH2PO4 in 25% ACN, pH 2.8),
a n dl o a d e do n t ot h ec o l u m n .B u ﬀer A was identical in
composition to the loading buﬀer, and buﬀer B was same as
buﬀer A except of containing 350mM KCl. Separation was
performed using a linear binary gradient of 0–80% buﬀer B
in buﬀer A at a ﬂow rate of 200μl/min for 60min. The ab-
sorbance at 214nm and 280nm was monitored, and a total
of 30 SCX fractions were collected along the gradient.
Each SCX fraction was dried down, dissolved in buﬀer C
(5% ACN, 0.1% FA), and analyzed on Qstar XL (Applied Bi-
osystems) as previously described by us [7]. Brieﬂy, peptides
were separated on a reverse-phase (RB) column (ZORBAX
300SB-C18 column, 5μm, 300 ˚ A, 0.1 × 15mm; Micromass)
using a 20AD HPLC system (Shimadzu). The HPLC gradient
was 5–35% buﬀer D (95% ACN, 0.1% FA) in buﬀer C at a
ﬂowrateof0.2μl/minfor65min.Surveyscanswereacquired
from 400 to 1800 with up to 4 precursors selected for MS/MS
from m/z 100–2000 using a dynamic exclusion of 30S. The
iTRAQ-labeled peptides fragmented under CID conditions
to give reporter ions at 113.1 and 1151 Th. The ratios of
peak areas of the iTRAQ reporter ions reﬂect the relative
abundances of the peptides and, consequently, the proteins
in the samples. Larger, sequence-information-rich fragment
ions were also produced under these MS/MS conditions and
gave the identity of the protein from which the peptide
originated.
2.4. Data Analysis. The ProteinPilot 3.0 software program
(ABI, USA) was used to perform Protein identiﬁcation and
quantiﬁcation analysis for the iTRAQ experiment. Identiﬁed
proteins were grouped by the software to minimize redun-
dancy; all peptides used for the calculation of protein ratios
were unique to the given protein or proteins within the
group. The protein conﬁdence threshold cutoﬀ for this study
is ProtScore 1.3 (unused) with at least one peptide with 95%
conﬁdence. The relative protein abundances were analyzed
by the signature ion ratio (m/z, 115/113): the ratio ≥1.2 and
≤0.8 as the diﬀerential expression proteins.
2.5. Western Blotting. Western blotting was performed in ten
pairs of microdissected HLSC and NBE. Brieﬂy, 30–50μg
of puriﬁed protein was separated by 10% SDS-PAGE and
transferred to PVDF membrane (Bio-Rad). The blots were
incubatedfor2hatroomtemperatureinTBST(20mMTris-
Cl, 140mM NaCl, pH 7.5, 0.05% Tween-20) containing 5%
skim milk and then were incubated with monoclonal mouse
anti-HSPB1 (dilution 1:1000, Abcam), monoclonal rabbit
anti-CKB (dilution 1:200, Santa Cruze), polyclonal rabbit
anti-human S100A8/A9, and polyclonal mouse anti-human
SCCA1(dilution1:200,SantaCruze)overnightat4◦C.After
washing three times in TBST, membranes were incubated
with a horse radish peroxidase conjugated secondary anti-
body (dilution 1:3,000, Amersham Biosciences) for 1h at
room temperature. The blots were developed using ECL
detection reagent and quantitated by densitometry using
ImageQuant image analysis system (Storm Optical Scanner).
Theβ-actinwasdetectedsimultaneouslyasaloadingcontrol.
2.6.TissueMicroarrayandImmunohistochemistry. Thetissue
microarray containing 30 lung squamous cell carcinoma,Journal of Biomedicine and Biotechnology 3
Table 1: The clinicopathological parameters of the 100 tissue
specimens.
Classiﬁcation Number
Gender
Male 84
Female 16
Age
≥55 68
<55 32
Histological type
Squamous cell carcinoma 30
High diﬀerentiated 5
Moderately diﬀerentiated 14
Poorly diﬀerentiated 11
Adenocarcinoma 8
Large cell carcinoma 6
S m a l lc e l lc a r c i n o m a 6
Lymph node metastasis 30
Positive
Normal lung tissue 20
30 metastatic carcinoma, 20 normal lung tissues, and 20
other types of lung cancer (lung adenocarcinoma, large cell
carcinoma,smallcellcarcinoma)wasfromAURAGENE.The
detailed information of the tissues is provided in Table 1.
Serial sections (4μm) were cut from the tissue microar-
ray, deparaﬃnized, rehydrated, and treated with an antigen
retrieval solution (10mmol/L sodium citrate buﬀer, pH 6.0).
Endogenousperoxidasewasblockedusing3%hydrogenper-
oxide in methanol for 20min. Nonspeciﬁc sites were blocked
for 20min using 1% normal serum in PBS. Sections were
incubated for 2h with a dilution of 1:200 polyclonal rabbit
anti-human S100A8/A9 or SCCA1 and then were incubated
with 1:1000 dilution of biotinylated secondary antibody fol-
lowed by avidin-biotin peroxidase complex (DAKO) accord-
ingtothemanufacturer’sinstructions.Finally,tissuesections
were incubated with 3 ,3  -diaminobenzidine (Sigma) until
a brown color developed and counterstained with Harris’
modiﬁed hematoxylin. In negative controls, primary anti-
bodies were omitted.
2.7. Evaluation of Staining. Immunostaining was blindly
evaluatedbytwoobserversinaneﬀorttoprovideaconsensus
on staining patterns. Each case was rated according to a score
that added a scale of intensity of staining to the area of
staining.Atleast10high-powerﬁeldswerechosenrandomly,
and >1000 cells were counted for each section. The positive
intensity of staining was graded on the following scale: 0,
no staining; 1+, pale yellow stained; 2+, tan-yellow stained;
and 3+, brown stained. The negative intensity of staining
was evaluated as follows: 0, <5% of tissue stained negative;
1+, 5%–25% of tissue stained negative; 2+, between 25%
and 50% stained negative; 3+, 50%–75% stained negative;
and 4+, >75% stained negative. The minimum score when
summed (positive stained + negative stained) was therefore
2 and the maximum, 7. A combined staining score (positive
stained + negative stained) of <2 was considered to be
negativestaining(−);ascorebetween2and3wasconsidered
tobeweakstaining(+);between3and6wasconsideredtobe
moderate staining (++); and between 6 and 7 was considered
to be strong staining (+++).
2.8. Statistical Analysis. One-way analysis of variance
(ANOVA) and LSD analysis (SPSS 12.0) were used in this
study. All statistical tests were two-sided. Diﬀerences were
considered statistically signiﬁcant for P values < 0.05.
3. Results
3.1. Identiﬁcation of Diﬀerentially Expressed Proteins in HLSC
and NBE Using iTRAQ Labeling and 2D LC-MS/MS. At o t a l
of 96 diﬀerentially expressed proteins were identiﬁed by
iTRAQ labeling and 2D LC-MS/MS, among which 49 up-
regulated and 47 downregulated proteins in HLSC (Table 2).
MS/MS spectrum used for the identiﬁcation and quantita-
tion of CKB is shown in Figure 1.
Biological functions and subcellular location of the iden-
tiﬁed 96 proteins were searched in EMBL-EBI and EXPASY
database. The most common diﬀerential expression proteins
were located in the cytoplasm, followed by nuclear proteins,
secreted proteins, and mitochondrial proteins. The locations
of the proteins were concomitant with their functions, which
were structural proteins, metabolic enzymes, signal trans-
duction proteins, cell adhesion, and proliferation-related
proteins (Figure 2).
3.2. Validation of Diﬀerentially Expressed Proteins Indentiﬁed
by Proteomics. Five proteins (HSPB1, S100A8/A9, CKB, and
SCCA1) identiﬁed by MS analysis were chosen for veriﬁca-
tion. Western blotting was performed to detect the expres-
sional levels of the four proteins in 10 cases of LCM-pu-
riﬁed NBE and HLSC. As shown in Figure 3, HSPB1 and
S100A8/A9wereupregulated,whereasCKBandSCCA1were
downregulated in the HLSC versus NBE (P<0.05), which is
consistent with the ﬁndings in MS analysis.
3.3. Detection of the Expression of the Diﬀerential Proteins
by TMA and Immunohistochemistry. T h ee x p r e s s i o n so f
SCCA1,S100A8/A9in30squamouscellcarcinoma,30meta-
static carcinoma, and 20 nonsquamous cell carcinoma (8
a d e n o c a r c i n o m a ,6l a r g ec e l lc a r c i n o m a ,6s m a l lc e l lc a r c i -
noma)weredetectedbyTMAandimmunohistochemisry.As
shown in Figure 4 and Table 3, the expressions of SCCA1
in lung squamous cell carcinoma, other types of lung carci-
noma, and metastatic carcinoma were lower than those in
normal lung tissue (P<0.05). As shown in Figure 5 and
Table 4, S100A8/A9 was expressed in all types of lung cancer
and normal tissues. Yet, the expression of S100A8 in lung
squamous cell carcinoma was stronger than that in normal
tissues and other types of lung cancer tissues (P<0.05).
As shown in Figure 6 and Table 5, the expression of S100A9
in cancer tissues including lung squamous cell carcinoma,4 Journal of Biomedicine and Biotechnology
Table 2: Diﬀerential expressed proteins in LCM-puriﬁed HLSC and NHBE identiﬁed by mass spectrometry.
No. of proteins Coverage (%) UniprotKB AC Name Peptides 115:113
1 62.34 IPI00554648.3 P05787 KRT8 60 0.4098
2 60.05 IPI00479145.2 P08727 KRT19 51 0.6193
3 56.53 IPI00745872.2 P02768 ALB 40 0.5735
4 59.8 IPI00009867.3 P13647 KRT5 68 0.7839
5 54.17 IPI00019502.3 P35579 MYH9 32 1.6587
6 39.41 IPI00007752.1 P68371 TUBB2C 37 0.1989
7 35.87 IPI00784154.1 P10809 HSPD1 30 1.5497
8 34.28 IPI00479186.5 P14618 PKM2 21 1.5827
9 34.2 IPI00844215.1 Q13813 SPTAN1 17 0.5947
10 42.7 IPI00450768.7 Q04695 KRT17 25 0.7824
11 30.05 IPI00219018.7 P04406 GAPDH 22 1.5761
12 28.96 IPI00845339.1 P08107 HSPA1A/1B 15 0.5216
13 27.82 IPI00022204.2 P29508 SERPINB3 16 0.3215
14 31.05 IPI00554788.5 P05783 KRT18 32 0.5866
15 50.34 IPI00300725.7 P02538 KRT6A 59 1.6359
16 24.25 IPI00553177.1 P01009 SERPINA1 13 0.651
17 23.08 IPI00654755.3 P68871 HBB 19 1.4246
18 22.65 IPI00455383.4 Q00610 CLTC 12 0.6788
19 23.9 IPI00003362.2 P11021 HSPA5 13 1.9385
20 20.99 IPI00025252.1 P30101 PDIA3 14 1.477
21 19.32 IPI00218914.5 P00352 ALDH1A1 11 0.3403
22 35.01 IPI00217963.3 P08779 KRT16 19 1.7771
23 18.49 IPI00872684.1 P15311 EZR 9 0.3327
24 16.7 IPI00013808.1 O43707 4ACTN4 14 0.4979
25 33.95 IPI00290077.1 P19012 KRT15 20 0.6399
26 16 IPI00219757.13 P09211 GSTP1 13 0.5584
27 15.06 IPI00000105.4 Q14764 MVP 7 0.516
28 14.96 IPI00645078.1 P22314 UBA1 8 1.345
29 14.66 IPI00788802.1 P29401 TKT 8 1.4856
30 13.96 IPI00020599.1 P27797 CALR 7 2.1548
31 13.57 IPI00169383.3 P00558 PGK1 8 0.6459
32 13.23 IPI00887678.1 LOC654188 8 2.2579
33 12.44 IPI00640741.1 Q06830 PRDX1 6 6.5599
34 12.12 IPI00604620.3 P19338 NCL 7 1.5576
35 12.1 IPI00893881.1 Q53G64 AGR2 14 0.4388
36 11.27 IPI00853068.1 Q86YQ1 HBA 11 1.372
37 11.23 IPI00816252.1 H2BFS 18 1.4498
38 11.14 IPI00657682.2 P08263 GSTA1 6 0.2536
39 11.01 IPI00643384.2 A6NLG9 BGN 5 0.2803
40 23.25 IPI00550661.2 P13646 KRT13 20 2.3013
41 38.63 IPI00384444.5 P02533 KRT14 19 1.448
42 10.4 IPI00027497.5 P06744 GPI 4 2.4216
43 9.95 IPI00027462.1 P06702 S100A9 7 3.1824
44 9.85 IPI00215948.4 P35221 CTNNA1 5 0.6596
45 9.76 IPI00453473.6 P62805 HIST1H4I 5 15.7322
46 9.42 IPI00794543.1 A8K1M2-cDNA FLJ75174 4 0.3772
47 9.08 IPI00549248.4 P06748 NPM1 9 2.033
48 8.97 IPI00221226.7 P08133 ANXA6 4 0.6198
49 8.63 IPI00032140.4 P50454 SERPINH1 4 2.9965Journal of Biomedicine and Biotechnology 5
Table 2: Continued.
No. of proteins Coverage (%) UniprotKB AC Name Peptides 115:113
50 8.55 IPI00025512.2 P04792 HSPB1 20 3.9981
51 8.14 IPI00798430.1 Q53H26 TF 4 0.6764
52 35.45 IPI00011654.2 P07437 TUBB 28 1.5243
53 8 IPI00022977.1 P12277 CKB 4 0.41
54 7.84 IPI00307162.2 P18206 VCL 5 2.4223
55 7.22 IPI00295400.1 P23381 WARS 3 1.4314
56 6.92 IPI00792011.1 Q8NF12 CAPS 5 0.3241
57 6.36 IPI00013415.1 P62081 RPS7 3 3.2407
58 6.27 IPI00025465.1 P20774 OGN 4 0.1986
59 6.24 IPI00853455.1 C9JIH9 CTSD 4 0.639
60 6.19 IPI00152295.1 Q8TC71 SPATA18 3 0.4421
61 9.34 IPI00829767.1 P01859 IGHG2 4 0.6251
62 6 IPI00789551.1 A8MXP9 MATR3 5 2.0326
63 6 IPI00871851.1 Q15019 SEPT2 4 1.3502
64 6 IPI00291006.1 P40926 MDH2 3 1.924
65 6 IPI00795633.1 Q8IWL5 CLU 3 0.3392
66 5.95 IPI00423462.5 Q6N092 IGHA1 3 0.7002
67 8.33 IPI00007047.1 P05109 S100A8 5 2.1281
68 5.73 IPI00654709.1 Q6PKA6 ALDH3A1 3 0.431
69 4.72 IPI00294834.6 Q12797 ASPH 2 2.3432
70 6.6 IPI00027350.3 P32119 PRDX2 3 1.7333
71 4.45 IPI00025086.3 P20674 COX5A 2 1.4661
72 4.4 IPI00009032.1 P05455 SSB 2 0.6693
73 4.4 IPI00060715.1 Q96CX2 KCTD12 2 0.7126
74 4.31 IPI00646059.1 Q5VXV2 SET 2 2.3791
75 4.13 IPI00216308.5 P21796 VDAC1 2 0.4488
76 4.08 IPI00032179.2 P01008 SERPINC1 2 0.6734
77 4.01 IPI00025796.3 O75489 NDUFS3 2 0.6022
78 4 IPI00020042.2 P43686 PSMC4 2 0.603
79 4 IPI00011126.6 P62191 PSMC1 2 0.6418
80 3.71 IPI00883950.1 Q8TB01 CKAP4 2 2.3486
81 2.95 IPI00420014.2 O75643 ASCC3L1 1 1.6656
82 2.73 IPI00003944.1 P11182 DBT 1 0.5156
83 2.58 IPI00479786.4 Q92945 KHSRP 1 1.9958
84 2.38 IPI00419237.3 P28838 LAP3 1 1.7329
85 2.34 IPI00024933.3 P30050 RPL12 1 1.7853
86 2.19 IPI00219221.3 P47929 LGALS7 1 0.7374
87 2.02 IPI00444204.1 Q6ZS74 ALB 1 2.0254
88 2.02 IPI00847322.1 Q4ZJI1 SOD2 1 0.6501
89 2.01 IPI00745729.2 A6PVW9 SELENBP1 1 0.5016
90 2.01 IPI00375746.4 Q6ZN66 GBP6 1 4.68
91 2 IPI00413654.3 Q13243 SFRS5 1 4.0553
92 2 IPI00010133.3 P31146 CORO1A 1 1.5283
93 2 IPI00221222.7 P53999 SUB1 1 7.5809
94 2 IPI00024976.5 Q9NS69 TOMM22 1 2.5511
95 2 IPI00888660.1 SDHA 1 2.0706
96 2 IPI00013895.1 P31949 S100A11 2 0.6028
Diﬀerentially labeled proteins are identiﬁed by QSTAR. The % coverage of analyzed peptides and Swiss-Prot accession number were shown for each protein.
Proteins displaying an average fold-diﬀerence of ≥1.2-fold up- (+) or ≤0.8-fold down- (-) regulation between pairs of conditions where P<0.05 are shown
(115: the group of HLSC; 113: the group of NHBE).6 Journal of Biomedicine and Biotechnology
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Figure 1: The fragment ion spectra of peptide sequence tag (PST) from CKB protein, highlighting the relative abundances of overexpression
in NHBE. The ion assignments are as follows: 113: NHBE; and 115: HLSC.
metastatic carcinoma, and other types of lung cancer was
stronger than in normal tissues (P<0.05).
4. Discussion
Recently, numerous successful explorations about carcino-
genic molecular mechanisms of HLSC on gene and tran-
scription were reported. Compared with genome and tran-
scriptome, which is relatively static and will be transcribed
intoavarietyoffunctionallydistinctproteins,proteomemay
provide a more realistic picture of function aberrations in
cancer cells. Proteomics has become the frontier era of the
postgenomic;thenewmethodsandachievementsareemerg-
ing in large number. Traditional 2-DE technique has been
used widely for comparative proteomics with a signiﬁcant
achievement, but also there is disadvantagedness. iTRAQ
quantitativeproteomicscanovercomethatdeﬁciencies(such
as identiﬁed membrane proteins) and increase the number
and types of diﬀerential expression proteins. In contrast
to 2-DE, iTRAQ technology has a better repeatability and
quantiﬁcation.
In the study, LCM was used to purify the target cells
fromHLSCtissuesandmatchedNHBE,respectively.Astable
isotope-labeledstrategyusingiTRAQ,followedby2D-LC/Q-
STAR mass spectrometry, was performed to separate and
identify the diﬀerential expression proteins. A total of 96
diﬀerential expression proteins in the LCM-puriﬁed HLSC
and NHBE were identiﬁed.
Among the diﬀerential expression proteins, HSPB1
(HSP27)isheatshockproteinfamilymember,whichhasim–
portant biological functions, a chaperone protein involved
in regulation of cell proliferation, diﬀerentiation, apoptosis
and signal transduction, and so forth. Induced epithelial-
mesenchymal transition (EMT) in human lung cancer cells
(adenocarcinoma cells), HSPB1, was high-regulated and in-
volved in the regulation of cell migration, adhesion and in-
vasion [8]. In the colon, prostate, and breast cancer, HSPB1
expression was associated with tumor occurrence and
metastasis. HSPB1 was high-regulated, suggesting the poor
prognosis and resistance to drugs [9–12]. Guo et al. found
that the functional HSPB1 promoter −1271G > C variant
may aﬀect lung cancer susceptibility and survival by modu-
lating endogenous HSPB1 synthesis levels [13]. The research
showed HSPB1 protein and its phosphorylation increased in
parallel with enhanced metastatic potentials of hepatocellu-
lar carcinoma (HCC) cells; HSPB1 knockdown signiﬁcantlyJournal of Biomedicine and Biotechnology 7
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Figure 2: Biological functions and subcellular location of the identiﬁed 96 proteins. (a) A pie chart representing the distribution of the
identiﬁed96proteinsaccordingtotheircellularlocations;(b)Apiechartrepresentingthedistributionoftheidentiﬁed96proteinsaccording
to their biological function.
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Figure 3:RepresentativeresultsofWesternblottinganalysisofHSPB1,CKB,S100A8/A9,andSCCA1inHLSC(CA)andNHBE(N).β-actin
was used as a loading control.
Table 3: SCCA1 expression in various tissues by IHC.
Classiﬁcation Number — + ++–+++ P value
Squamous cell carcinomas 30 21 5 4 0.038a
High diﬀerentiated 3 3 0 0 0.406b
Moderately diﬀerentiated 11 9 2 0
Poorly diﬀe r e n t i a t e d 1 0 622
Normal lung tissue 20 9 10 1
Metastatic carcinoma 29 16 5 8 0.029c
Other types 20 12 6 2 0.001d
aP<0.05 by LSD, squamous cell carcinomas versus normal lung tissue. bP>0.05 by ANOVA, high diﬀerentiated versus moderately versus poorly. cP<0.05
by LSD, metastatic carcinoma versus normal lung tissue. dP<0.05 by LSD, other types versus normal lung tissue.8 Journal of Biomedicine and Biotechnology
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Figure 4: Immunohistochemistry staining in tissue chip of SCCA1 protein expression in lung cancer tissue and normal tissues ((a) normal
lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell
carcinoma tissues).
Table 4: S100A8 expression in various tissues by IHC.
Classiﬁcation Number — + ++–+++ P value
Squamous cell carcinomas 30 1 5 24 0.000a
High diﬀerentiated 3 0 0 3 0.705b
Moderately diﬀerentiated 11 2 7 2
Poorly diﬀe r e n t i a t e d 1 0 622
Normal lung tissue 20 1 11 8
Metastatic carcinoma 29 0 11 18 0.007c
Other types 20 3 12 5 0.000d
aP<0.05 by LSD, squamous cell carcinomas versus normal lung tissue. bP> 0.05 by ANOVA, high diﬀerentiated versus moderately versus poorly. cP< 0.05
by LSD, metastatic carcinoma versus normal lung tissue. dP< 0.05 by LSD, other types versus normal lung tissue.Journal of Biomedicine and Biotechnology 9
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Figure 5: Immunohistochemistry staining in tissue chip of S100A8 protein expression in lung cancer tissue and normal tissues ((a) normal
lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell
carcinoma tissues).
Table 5: S100A9 expression in various tissues by IHC.
Classiﬁcation Number — + ++–+++ Pvalue
Squamous cell carcinomas 30 0 2 28 0.01a
High diﬀerentiated 3 0 3 0 0.705b
Moderately diﬀerentiated 11 9 2 0
Poorly diﬀe r e n t i a t e d 1 0 820
Normal lung tissue 20 0 10 10
Metastatic carcinoma 29 0 4 25 0.000c
Other types 20 0 2 18 0.000d
aP< 0.05 by LSD, squamous cell carcinomas versus normal lung tissue. bP> 0.05 by ANOVA, high diﬀerentiated versus moderately versus poorly. cP<
0.05 by LSD, metastatic carcinoma versus normal lung tissue. dP< 0.05 by LSD, other types versus normal lung tissue.10 Journal of Biomedicine and Biotechnology
(a) (b)
(c) (d)
(e) (f)
Figure 6: Immunohistochemistry staining in tissue chip of S100A9 protein expression in lung cancer tissue and normal tissues ((a) normal
lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell
carcinoma tissues).
suppressed cells migration and invasion and induced cell
apoptosis [14]. Ye et al. showed that upregulated HSPB1
expression was potentially involved in human oral squamous
cell carcinoma growth and metastasis [15]. In our study,
HSPB1 was upregulated in HLSC compared with NHBE,
conﬁrmed by Western blot analysis. It was suggested that
HSPB1 might play a certain role in carcinogenic of HLSC.
CKB (creatinekinase B) is a member of the creatine kin-
asefamily,thatexistswidelyinasskeletalmuscle,myocardial,
nerve tissue, and mitochondria. CKB participated in energy
signaling pathways and catalyzed phosphate group reversibly
from creatine phosphate to ADP to generate ATP and
creatine. CKB expressed in the organization demanded high
energy, as a nuclear “energy supplier”. CKB was downregu-
lated protein in human prostate cancer cells associated with
progression [16]. Reduced expression has been reported in
colon, and renal cancer compared with matched adjacent
normal tissues [17, 18]. Our ﬁnding of reduced levels of
CKB in human lung squamous carcinoma suggests a novel
association for CKB with HLSC which needs to be investi-
gated further.
SCCA1 (Squamous cell carcinoma antigen 1) also named
SERPINB3 (serine protease inhibitor3) belonged to serine
protease inhibitor family, that was physiologically found in
normal squamous epithelium but overexpressed in squa-
mous cell carcinoma (lung, cervical, esophagus, etc.). The
biological role of this serpin in carcinogenesis has not been
deﬁned. On the one hand, SCCA1 can decrease NK tu-
mour invasion [19] and inhibit apoptosis by inhibiting P38
phosphorylation and release of C cytochromes [20, 21].
Elevated levels of SCCA1 have been reported in liver, esoph-
agus, mammary carcinoma, and so forth, associated with
malignant cancer, prognosis, and recurrence [22]. In a
previous study, it was reported that SCCA1 expression levelsJournal of Biomedicine and Biotechnology 11
were associated with tumor progression. Increasing number
ofreportssuggeststhatSCCAhasbeenimplicatedasatumor
marker for squamous [23]. Interestingly, our ﬁnding is that
SCCA1 levels were downregulated in human lung squamous
carcinomacomparedwithcorresponding normaltissue.Our
laboratory reported that SCCA1 levels were downregulated
in nasopharyngeal carcinoma by promoter methylation [24].
Whether lung squamous carcinoma exists in promoter
methylation, further analysis of the expression of SCCA1 in
preneoplasticlesionsforsquamouscellcarcinomaofthelung
is needed.
Heterodimer S100A8/A9 is the member of calcium-
bindingproteinS100proteinfamily,theinﬂammationfactor,
and inhibition of casein kinase I, II activity. Physically,
S100A8/A9 is expressed as the early stages of cell diﬀeren-
tiation in bone marrow and granulocytes and monocytes in
circulation.Someinﬂammatorydiseases,suchasrheumatoid
rheumatoid arthritis, inﬂammatory bowel disease, chronic
pneumonia, their epithelial cells, and the cells of inﬂamma-
tory exudate in early stage of inﬂammatory diseases express
S100A8/A9. ElevatedlevelsofS100A8/A9 havebeenreported
in lung, stomach, breast, pancreatic, prostate cancer, and so
forth. In addition, S100A9 has correlation with the poor
diﬀerentiation of breast, lung, and thyroid cancer [7, 25–27].
Iikawa reveals a novel role for myeloid-derived S100A8/A9 in
activating MAPK and NF-κB signaling pathways associated
with colon tumorigenesis and in promoting tumor growth
and metastasis [28]. Our ﬁndings are consistent with the
reported that S100A8/A9 is upregulated in human lung
squamous carcinoma compared with corresponding normal
tissue. Although many possible functions have been pro-
posed for S100A8/A9, its biological role still remains to be
deﬁned.
5. Conclusions
In conclusion, our data suggest that the several diﬀerential
expression proteins may play a key role in human
lung squamous carcinoma. Known to that during the
development of human lung squamous cell carcinoma,
bronchial epithelial cells exhibit a progressive series of
morphologically distinct changes: hyperplasia, squamous
metaplasia, dysplasia, carcinoma in situ, and ﬁnally invasive
squamous cell carcinoma. We seek to identify diﬀerential
expression proteins that can be used to monitor these
premalignant changes under the assumption that these
morphologic changes are accompanied by abnormal
expression proteins. Thus, additional research using a larger
number of tumor specimens is needed to conﬁrm our
ﬁndings more assuredly and we will make greater eﬀorts
to elucidate the precise molecular mechanisms of how the
protein acts on the carcinogenesis in future works.
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